More recently, a phase II clinical trial, NSABP Foundation Trial FB-10, studied the safety and tolerability of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer, and reported a recommended dose for this regimen to provide basis for future studies that would better define the activity of this combination [153]. The gene discussed is ERBB2; the disease is breast carcinoma.